All for Joomla All for Webmasters

D3 - Session 1 - Covid19 Associated Coagulopathies: A Year in Review

Rate this item
(2 votes)

Did you attend this webinar? Get your certificate

 

Questions/answers on the Session 1 - Covid19 Associated Coagulopathies: A Year in Review

A1. Based on what we know now, the increased risk of bleeding is as expected in the general population of acute medically ill patients. Those patients that are not admitted for COVID-19, we know that the use of low molecular weight heparin does increase non significantly but does increase a little bit the risk of bleeding, especially in older patients but the clinical benefit remains absolutely. The 1st results that we do have on COVID-19 patients admitted to medical wards are pretty much in line with that. I would feel quite confident with regards to the ICU patients again, as I mentioned, there isn't high risk of bleeding and we knew that before even for Non-COVID-19 patients but we have to be very careful because these patients have usually low platelet counts and worsening renal function. For this reason I definitely would stick with prophylactic doses unless higher doses are strongly indicated. The risk of bleeding, especially in ICU patients always needs to be carefully balanced. For the other patients I would use the same rules that we use for Non-COVID-19 and measure renal function. Also, pay attention to concomitant antiplatelet agents, of course.
Walter Ageno

A2. There are at least two or three trials trying to address this interesting topic. I'm sure about two there will be maybe a third one. This is certainly the most difficult population to enroll in a trial because these patients are at home so you need help from the general practitioners, but this is a question that has never been completely answered even in the past. Of course, we do manage patients at home who may have the same risk factors as hospitalized patients and this is also true for COVID-19 patients. Some of these patients remain bedridden for many days with high fever and because of an acceptable respiratory function they remain at home, but their risk maybe increased. The current guidance documents that I rapidly mentioned, do not suggest the routine use at home and I totally agree with that as there is no evidence to routinely use heparin at home. However, I take the responsibility, this is my opinion, to consider for some patients the possibility to use prophylactic doses, especially in those patients who do have additional risk factors, especially obese patients. Ideally these patients should have at least some laboratory tests done just to have information on the platelet count, renal function, coagulation if possible. That would be certainly safer, but I would not be against the use of LMWH at home in some high-risk patients.
Walter Ageno

A3. I would like to give several answers related to this question. The first one is if the patient is already receiving oral anticoagulation, either with vitamin K antagonists or direct oral anticoagulants for other reasons, these patients need to stay on their drugs unless there is a contraindication and usually these contraindications come from the use of drugs that may interact with the director anticoagulants for example. In these cases, patients may be switched to low molecular weight heparin. But if no interference of the new treatments is expected, I definitely would suggest continuing with their with their anticoagulation drugs. The second one is related to the treatment with direct oral anticoagulants of a Venous Thromboembolism that occurs during hospitalization. Also in this case this is absolutely a possibility. Again, just pay attention to potential contraindications which may be related to concomitant drugs that may interfere with the activity of the direct oral anticoagulants or other contradictions that may come up, such as organ failure, but other than that, I would suggest the use of direct oral anticoagulants for the treatment of venous thromboembolism in these patients. For prophylaxis this is another issue. the first thing I would say that the direct oral anticoagulants are currently not approved for prophylaxis in medically ill patients in most countries. In some countries they are, for example, betrixaban and rivaroxaban are approved the United States. In Italy I could not use them just for the purpose of prophylaxis. However, there are some observational data on Patients who have received some of the Direct oral anticoagulants. I have in mind a study published in Thrombosis and Hemostasis with apixaban and the use of apixaban was as safe and as effective as low molecular weight heparin, but this was an observational study with all its limitations considered.
Walter Ageno


From the laboratory standpoint the main issue here is that DOACs usually do not require Laboratory assessment to adjust the dosage as is for vitamin K antagonist and there are some reports in the literature that there may be some interference from, for instance, antiviral drugs on the blood concentration of DOAC. I think that at the moment, on one hand we should measure DOAC concentration in plasma to be sure that the expected concentration is there when the patient are treated with other drugs. But on the other hand, even though we decided to measure the plasma concentration of DOAC at the moment we do not have established reference intervals, therapeutic intervals to be used in this patient because the literature is very scanty even in non-COVID-19 patients about the therapeutic interval as far as the concentration of DOAC is concerned. I think that at the moment it's really very difficult and the laboratory cannot help unless we can define the therapeutic interval which is not established in reports from the literature or from the regulatory authorities. What we know at the moment is only the expected plasma concentrations which however are not connected with the clinical events in this patient. For the time being, I think that it's really very difficult to answer this question.
Armando Tripodi

Additional Info

  • Business Line: Hemostasis
  • Language: English
  • Speaker(s): Armando TripodiWalter Ageno
  • Recorded Date: Friday, 09 April 2021
  • Duration: 1:28:53
Read 326 times

Werfen.com. All rights Reserved. Privacy Policy | Cookies Policy | Terms of Service

No Internet Connection